Starpharma still reaching for the sky

Growth continues for this biotech hopeful

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

As a biotechnology (biotech) company, Starpharma’s (ASX: SPL) products are incredibly exciting not just from the potential benefits to society but also from the profits that could flow to shareholders if commercial success is achieved.

Starpharma is currently developing drugs aimed at treating an array of medical issues, particularly relating to women’s health. The company has also cleverly adapted the technology and applied it to agricultural crop protection.

The recent full year results announcement did not provide investors with any new updates in what was a big 2012 for Starpharma as it progressed towards commercialising its products.

For an investor who is not a specialist in a particular medical or scientific field, investing in biotech companies can sometimes be overwhelming. However, given the often large profits that are realised from a blockbuster drug, it is a sector with obvious appeal.

Some of the greatest businesses in the world are ‘drug’ companies and many of the world’s top investors such as Seth Klarman are regular investors in the sector. For Fools who feel they need a crystal ball to invest in early stage biotech companies such as Starpharma, Pharmaxis (ASX:PXS) or Acrux (ASX: ACR), then perhaps consider some established firms who already have high quality, approved products with significant sales.

For example, bio-plasma company CSL Ltd (ASX: CSL) sells blood plasma, antivenin and vaccines and with revenues of over $4 billion and profits of approximately $1 billion it is certainly an established and profitable business.

Likewise, but on a smaller scale, vitamin manufacturer Blackmores (ASX: BKL) continued to grow in the last financial year. Sales were up 11% to $261 million and the company reported record profits of $28 million.

Foolish takeaway

A key factor in investing, as Warren Buffett says, is limiting yourself to your circle of competence. If that includes complex scientific research and an understanding of biotech then investing in early-stage biotech such as Starpharma can be a successful endeavour.

If this isn’t your strength, then companies such as CSL with established earnings streams may be more appropriate.

If you’re in the market for some high yielding ASX shares, look no further than our “Secure Your Future with 3 Rock-Solid Dividend Stocks” report. In this free report, we’ve put together our best ideas for investors who are looking for solid companies with high dividends and good growth potential. Click here now to find out the names of our three favourite income ideas. But hurry – the report is free for only a limited time.

More reading

Motley Fool contributor Tim McArthur doesn’t own shares in any company mentioned. The Motley Fool’s purpose is to help the world invest, better. Take Stock is The Motley Fool’s free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. Click here now to request your free subscription, whilst it’s still available. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

asx share price competitions represented by businessmen arm wrestling
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

person reading news on mobile phone
⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »